Filing Details

Accession Number:
0001209191-23-052349
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-10-06 16:58:40
Reporting Period:
2023-10-04
Accepted Time:
2023-10-06 16:58:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1861560 Nuvalent Inc. NUVL Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1862146 Durant Christopher Turner C/O Nuvalent, Inc.
One Broadway, 14Th Floor
Cambridge MA 02142
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2023-10-04 7,995 $6.89 22,508 No 4 M Direct
Class A Common Stock Disposition 2023-10-04 2,665 $51.32 19,843 No 4 S Direct
Class A Common Stock Disposition 2023-10-04 2,265 $53.70 17,578 No 4 S Direct
Class A Common Stock Disposition 2023-10-04 600 $54.32 16,978 No 4 S Direct
Class A Common Stock Disposition 2023-10-04 500 $55.84 16,478 No 4 S Direct
Class A Common Stock Disposition 2023-10-04 500 $57.18 15,978 No 4 S Direct
Class A Common Stock Disposition 2023-10-04 1,465 $57.70 14,513 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class A Common Stock Stock Option (Right to Buy) Disposition 2023-10-04 7,995 $0.00 7,995 $6.89
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
303,105 2031-04-29 No 4 M Direct
Footnotes
  1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 21, 2021.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.15 to $51.49, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) of this Form 4.
  3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.01 to $54.00, inclusive.
  4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.01 to $54.96, inclusive.
  5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.44 to $56.00, inclusive.
  6. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.49 to $57.40, inclusive.
  7. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.54 to $58.00, inclusive.
  8. The shares underlying this option vest as follows: 25% of the shares vested on March 22, 2022, and the remainder have vested or shall vest over the next three years thereafter in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.